Salicylic Acid
Also known as 2-Hydroxybenzoic acid, Orthohydroxybenzoic acid, BHA exfoliant
“CIR Expert Panel says: safe within use limit.”
Salicylic Acid (2-hydroxybenzoic acid; CAS 69-72-7; C7H6O3) is a beta-hydroxy acid (BHA) used in cosmetics primarily as an exfoliant active (keratolytic) and as a preservative. As a keratolytic it dissolves intercellular cement of the stratum corneum, accelerating desquamation; it is widely used in acne, anti-dandruff, and skin-smoothing formulations at concentrations of 0.5–3%. The CIR Expert Panel assessed salicylic acid and 17 salicylate ingredients (IJT 22(Suppl 3):1-108, 2003; updated Final Report 04/2019; amended 2025) and concluded they are safe when formulated to be non-irritating and non-sensitizing, with actual safe concentration determined by quantitative risk assessment (QRA); practice-of-use concentrations ranged from 0.0008% to 3%. The SCCS issued opinion SCCS/1646/22 (June 2023) with explicit product-type concentration limits: up to 3% in rinse-off hair products, up to 2% in most other cosmetics, and up to 0.5% as a preservative or in body lotions, eye, lip, oral, and non-spray deodorant products; spray/inhalation products are excluded. The SCCS additionally flagged salicylic acid as an eye irritant and noted insufficient data to establish safety for children aged 3-10. Unlike the AHA class, salicylic acid does not have a systemic photosensitivity concern; it does have known aspirin-cross-reactivity and salicylate-accumulation concerns at high cosmetic exposures. The FDA regulates salicylic acid under OTC drug monograph rules for acne and dandruff (separate regulatory context from cosmetic use).
Keratolytic exfoliant (BHA): dissolves intercellular lipid cement in the stratum corneum, effective for comedolytic (anti-acne), anti-dandruff, and skin-smoothing applications at 0.5–3%
Preservative function: at ≤0.5% inhibits microbial growth in aqueous cosmetic formulations; listed permitted preservative under EU Cosmetics Regulation Annex V
Oil-soluble BHA: unlike AHA exfoliants (glycolic, lactic acid), salicylic acid is lipid-soluble and can penetrate sebum-filled pores, making it particularly effective for oily and acne-prone skin
Well-characterised safety profile: CIR assessment (2003, updated 2019, amended 2025) and SCCS opinion (SCCS/1646/22, 2023) together provide extensive multi-jurisdictional safety evidence across 18 salicylate compounds
CIR safe at current practices (up to ~3%): the QRA-based approach confirms cosmetic exposure is well within safety thresholds — estimated daily cosmetic exposure at 3% use concentration is roughly 20% of the salicylate exposure from a single baby aspirin
- · Eye irritant with potential to cause serious eye damage (SCCS/1646/22): product formulations for eye-area application require concentration limit of ≤0.5% and appropriate eye safety substantiation
- · Aspirin cross-reactivity: individuals with aspirin sensitivity may react to topical salicylic acid, though systemic absorption from cosmetic-use concentrations is typically low
- · Not approved for use in sprayable/inhalable cosmetic products (SCCS/1646/22 explicit exclusion)
Salicylate systemic accumulation risk: high-frequency application of multiple salicylate-containing products may contribute to salicylate body burden, particularly in children; SCCS/1646/22 concluded safety for children aged 3-10 is not established due to insufficient exposure data
CIR and SCCS use different frameworks for setting limits: CIR applies QRA methodology with no fixed concentration cap (safe at current practice levels up to ~3%); SCCS sets explicit product-type caps (3%/2%/0.5% depending on product type). These are complementary rather than conflicting but a formulator must meet the more conservative SCCS limits for EU market products
FDA OTC drug monograph context: at concentrations of 0.5–2% for acne or 1.8–3% for dandruff/psoriasis, salicylic acid is an OTC drug active in the US, not a cosmetic ingredient — regulatory status depends on label claims and concentration, and this packet covers only the cosmetic-use context
CIR Quick Reference Table (October 2024) — Salicylic Acid row: Finding=SQ, conditions per QRA, Citation=IJT 22(Suppl 3):1-108, 2003; Fina…
“The Panel concluded that the following ingredients are safe in cosmetics in the present practices of use and concentration described in the safety assessment, when formulated to be non-irritating and non-sensitizing, which may be based on a quantitative risk assessment (QRA)...Salicylic Acid... IJT 22(Suppl 3):1-108, 2003; Final Report 04/2019 Available from CIR”— QRT-Update-100824_0.pdf, Salicylic Acid row (Conclusion and Citation columns)
SCCS Opinion on Salicylic Acid (CAS No. 69-72-7, EC No. 200-712-3), SCCS/1646/22, adopted 6-7 June 2023
“SCCS/1646/22, adopted 6-7 June 2023: safe as preservative at max 0.5%; rinse-off hair products up to 3.0%; most other products up to 2.0%; body lotions, eye, lip, oral, non-spray deodorant up to 0.5%; excludes sprayable products; eye irritant with potential to cause serious damage; safety for children aged 3-10 not established.”— SCCS/1646/22, Conclusion section — retrieved from EC publications landing page